The team from Liu et al. found that SNHG17 could inhibit C-MYC ubiquitination by interacting with LRPPRC in HCC and promote HCC proliferation through snHG17-LRPPRC-C-MYC regulatory axis, which provides a potential target for cancer therapy (Liu et al. 2021). This evidence concerns the gene LRPPRC and hepatocellular carcinoma.